Moderna Applies For Phase 2 Study Of Coronavirus Vaccine Candidate
Moderna Inc (NASDAQ: MRNA) said Monday that it has submitted an investigational new drug application to the FDA, seeking the regulatory agency's consent to proceed with Phase 2 and late-stage studies of its novel coronavirus vaccine candidate mRNA 1273.
